Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $167.00

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target upped by Citizens Jmp from $144.00 to $167.00 in a research note released on Wednesday morning,Benzinga reports. The brokerage currently has a market outperform rating on the stock.

A number of other analysts also recently commented on the stock. Wall Street Zen downgraded shares of Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, September 6th. Raymond James Financial reiterated a “strong-buy” rating and issued a $189.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday. HC Wainwright increased their price objective on shares of Mirum Pharmaceuticals from $200.00 to $202.00 and gave the company a “buy” rating in a report on Wednesday. Stifel Nicolaus raised their price objective on shares of Mirum Pharmaceuticals from $136.00 to $156.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. Finally, Cantor Fitzgerald boosted their target price on Mirum Pharmaceuticals from $155.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Mirum Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $154.94.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ MIRM traded up $0.18 during midday trading on Wednesday, reaching $93.72. 722,713 shares of the company traded hands, compared to its average volume of 710,635. Mirum Pharmaceuticals has a 52 week low of $63.23 and a 52 week high of $130.00. The stock has a 50-day moving average price of $89.29 and a 200 day moving average price of $98.46. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74. The company has a market cap of $6.09 billion, a price-to-earnings ratio of -6.06 and a beta of 0.75.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.38). The company had revenue of $185.72 million during the quarter, compared to analyst estimates of $178.07 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%. The business’s revenue for the quarter was up 39.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.05 EPS. Sell-side analysts anticipate that Mirum Pharmaceuticals will post -1.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 40,000 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $100.00, for a total value of $4,000,000.00. Following the completion of the sale, the senior vice president directly owned 1,274 shares of the company’s stock, valued at approximately $127,400. This represents a 96.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Eric Bjerkholt sold 6,001 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total transaction of $599,499.90. Following the transaction, the chief financial officer owned 36,355 shares of the company’s stock, valued at approximately $3,631,864.50. This trade represents a 14.17% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 116,659 shares of company stock valued at $11,404,100 over the last three months. Company insiders own 8.32% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Contravisory Investment Management Inc. lifted its stake in Mirum Pharmaceuticals by 2.3% during the second quarter. Contravisory Investment Management Inc. now owns 4,604 shares of the company’s stock valued at $539,000 after purchasing an additional 103 shares during the last quarter. Knights of Columbus Asset Advisors LLC boosted its holdings in Mirum Pharmaceuticals by 0.5% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 23,944 shares of the company’s stock worth $2,047,000 after buying an additional 113 shares in the last quarter. ABS Investment Management LLC acquired a new position in Mirum Pharmaceuticals in the second quarter worth approximately $245,847,000. Integrated Wealth Concepts LLC acquired a new position in Mirum Pharmaceuticals in the second quarter worth approximately $27,000. Finally, Commonwealth Equity Services LLC increased its holdings in shares of Mirum Pharmaceuticals by 10.8% in the third quarter. Commonwealth Equity Services LLC now owns 2,471 shares of the company’s stock valued at $211,000 after buying an additional 241 shares in the last quarter.

Key Stories Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $202 price target, while still projecting a path to higher earnings over the longer term; its FY2030 EPS estimate rose to $10.76 from $10.03. HC Wainwright estimates
• Positive Sentiment: Mirum’s latest quarter showed revenue up 39.6% year over year to $185.72 million, ahead of analyst expectations. The stock also moved above its 50-day moving average after the earnings release, a potentially supportive technical signal. Stock crosses 50-day moving average
• Neutral Sentiment: Leerink Partners lowered its price target to $140 from $154 but kept an “Outperform” rating. That reflects reduced upside expectations while retaining a positive view of the shares. Leerink Partners rating
• Negative Sentiment: HC Wainwright substantially cut EPS estimates for 2026 and 2027, shifting its FY2027 forecast from a $1.16 profit to a $1.28 loss. It also reduced its FY2028 estimate from $5.38 to $2.64 and FY2029 from $7.21 to $6.85, indicating weaker expected earnings in the coming years despite the maintained Buy rating. HC Wainwright revised EPS estimates
• Negative Sentiment: Quarterly EPS was a loss of $0.87, wider than the expected $0.49 loss. The earnings shortfall tempers the revenue beat and may weigh on investor sentiment. Earnings and stock outlook
• Negative Sentiment: CEO Christopher Peetz sold 20,000 shares worth $1.8 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan, which may soften its significance but can still draw investor attention. CEO share sale

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly disorders affecting the liver and bile acid pathways. The company’s medicines are designed to address conditions with limited treatment options and to improve outcomes for children and adults living with serious chronic diseases.

Mirum’s lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor used to treat cholestatic pruritus, or severe itching caused by impaired bile flow, in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.